Retrospective Real-word Study of Linezolid for the Treatment of Tuberculous Meningitis
试验速览
- 阶段
- 不适用
- 入组人数
- 150
- 试验地点
- 1
- 主要终点
- Survival
研究概览
简要总结
Tuberculous meningitis (TBM) is the most serious form of Mycobacterium tuberculosis infection, causing mortality and disability in more than half of the patients. Current standard treatment for TBM is based on those developed to treat pulmonary tuberculosis, which does not take into account the differential ability of anti-tuberculosis drugs to penetrate the brain. With both good central nervous system penetrance and anti-tuberculosis efficacy that have been demonstrated in drug-resistant tuberculosis, linezolid may be a promising antimicrobial in TBM treatment. The purpose of this study is to evaluate the effectiveness of linezolid in the treatment of TBM.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •all patients diagnosed as TBM from the electronic medical record system.
排除标准
- •Does not meet the established diagnostic criteria;
- •Combine other pathogen central infections;
- •Follow-up confirmed that the final diagnosis considers other diseases (such as tumors, autoimmune encephalitis, etc.);
- •Our hospital has less than one week of anti-tuberculosis treatment;
- •Lack of information
研究组 & 干预措施
Background-linezolid group
Linezolid was added in the middle of the treatment course but not in the initial treatment regimen.
干预措施: Linezolid (Drug)
Linezolid initial group
Linezolid was in initial treatment regimen.
干预措施: Linezolid (Drug)
结局指标
主要结局
Survival
时间窗: 5 years
次要结局
- Number of participants with Medical Research Council grade deterioration(From the beginning of anti-tuberculosis treatment to the first documented progression, assessed up to 5 years.)
研究者
Wen-hong Zhang
Director of Division of Infectious Diseases
Huashan Hospital